Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective follow-up study of golimumab in psoriatic arthritis
NL-OMON37425Phase 4Not yet recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in psoriatic arthritis (PsA), sponsored by Jan van Breemen Institute. Primary endpoints: ACR20 response, PASI improvement and 1 more. Planned start Feb 2012; status: not yet recruiting.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON37425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37425.